Genelux Corporation to Participate in Upcoming Conferences WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the Company will participate in two upcoming conferences. Oppenheimer Healthcare Life Sciences Conference: Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will participate in a virtual fireside chat on Wednesday, February 25, 2026, at 11:20 a.m. ET.TD Cowen 46th Annual Health Care Conference: Th...
A director at Prospect Capital Corp bought 942,800 shares at 2.917USD and the significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Moody's Ratings (Moody's) today assigned a Prime-2 commercial paper rating to the $600 million commercial paper (CP) note program of Healthcare Realty Holdings, L.P., the main operating subsidiary of Healthcare Realty Trust Incorporated (collectively "Healthcare Realty"). We also affirmed Healthcare...
Prospect Capital Announces Financial Results for December 2025 NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced financial results for our fiscal quarter ended December 31, 2025. FINANCIAL RESULTS All amounts in $000’s exceptper share amounts (on weighted average basis for period numbers)Quarter EndedQuarter EndedQuarter Ended December 31, 2025September 30, 2025December 31, 2024 Net Investment Income (“NII”)$90,888$79,350$86,431NII per Common Share$0.19$0.17$0.20Interest as % of Total Investment Income8...
Prospect Capital Schedules Second Fiscal Quarter Earnings Release and Conference Call NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (the “Company” or “Prospect”) today announced it expects to file with the Securities and Exchange Commission its report on Form 10-Q containing results for the fiscal quarter ended December 31, 2025 and to issue its earnings press release on Monday, February 9, 2026, after the close of the markets. The Company will host a conference call on Tuesday, February 10, 2026 at 9:00 a.m. Eastern Time. The conference call dia...
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will participate in a virtual fireside chat hosted by Boris Peaker, PhD, Managing Director and Senior Equity Research Analyst at Titan Partners, on Monday, January 19, 2026 at 9:00 a.m. PT. A live webcast of the fireside ...
Prospect Capital Announces Annual Meeting Update NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced that it held its adjourned annual meeting of stockholders (the “Annual Meeting”) on January 8, 2026. The proposals that were considered at the Annual Meeting are described in detail in the Company’s definitive proxy statement for the Annual Meeting as filed with the Securities and Exchange Commission on September 18, 2025 (the “Proxy”). As of September 17, 2025, there were 465,087,009 shares of the Company's c...
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a price to the public of $3.00 per share. All of the shares in the offering are to be sold by Genelux. The gross proceeds to Genelux from the offering are expected to be approximately $20.0 million, before deducting underwriting disc...
Genelux Corporation Announces Proposed Public Offering of Common Stock WESTLAKE VILLAGE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced a proposed underwritten public offering of its common stock. In addition, Genelux expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the proposed offering. All shares are being offered by Genelux. The proposed offering is subject to ...
Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials -- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials; enrollment ongoing – -- In platinum-relapsed or platinum-refractory advanced SCLC, two of three partial responses (PRs) occurred in the highest dose cohort tested as of the data review cutoff date (tumor shrinkage of ~55% and ~85%), with three PRs out of nine subjects (33%) across ...
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones. “We are excited to welcome Jason, who is widely recognized for his strategic approach to clinical development and commitm...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.